Protective Effect of Tanshinone IIA on the Early Stage of Experimental Diabetic Nephropathy
| Autor: | Su Kang Kim, Kyung-Hee Jung, Byung-Cheol Lee |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Blood Glucose
Collagen Type IV Glycation End Products Advanced medicine.medical_specialty Pharmaceutical Science Enzyme-Linked Immunosorbent Assay Kidney Protective Agents Salvia miltiorrhiza Monocytes Diabetes Mellitus Experimental Transforming Growth Factor beta1 Diabetic nephropathy chemistry.chemical_compound Glycation Internal medicine Diabetes mellitus medicine Animals Diabetic Nephropathies Pharmacology business.industry Angiotensin II Macrophages General Medicine Phenanthrenes medicine.disease Streptozotocin Immunohistochemistry Rats Proteinuria medicine.anatomical_structure Endocrinology Neutrophil Infiltration chemistry Abietanes Advanced glycation end-product business medicine.drug |
| Zdroj: | Biological and Pharmaceutical Bulletin. 32:220-224 |
| ISSN: | 1347-5215 0918-6158 |
| Popis: | Diabetic nephropathy (DN) has become the leading cause of end stage renal failure, and prevention or retardation of DN has become a major goal in biomedical research. In this study, Tanshinone IIA, a component extracted from Salvia miltiorrhiza, was studied in experimental rats in which DN was induced by streptozotocin (STZ) treatment. The DN rats were treated with 10 mg/kg of Tanshinone IIA for 12 weeks to analyze its reno-protective effect with different parameters. Renal hypertrophy and 24-h urinary protein excretion were ameliorated by Tanshinone IIA. Moreover, advanced glycation end-products (AGEs), angiotensin II (Ang II), transforming growth factor beta(1) (TGF-beta(1)), collagen IV, and monocyte/macrophage (ED-1) either in the serum or kidney were significantly reduced. These results suggest that Tanshinone IIA might have protective effects on several pharmacological targets during the progression of DN, and could be a potential drug for the prevention of DN. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|